(CSSC-001) Convalescent Plasma to Stem Coronavirus: A Randomized Controlled Double Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. control( SARS-CoV-2 non-immune plasma) among Adults Exposed to COVID-19 and (CSSC-004) Convalescent Plasma to Stem Coronavirus: A Randomized Controlled Double Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 non-immune plasma)

Grant

Date/time Interval

  • May 15, 2020 - August 15, 2020
  • Total Award Amount

  • 80000.00
  • Direct Costs

  • 61538.00
  • Sponsor Award Id

  • Contributor

  • Edgar Overton   Investigator  
  • Marisa Marques   Investigator  
  • Paul Goepfert M.D.   Investigator  
  • Sonya Heath   Principal Investigator  
  • Todd McCarty   Investigator